ShortedShorted

RESMED INC CDI 10:1 FOR. EXEMPT (RMD) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
just now

Why Are ResMed (ASX:RMD) and TechnologyOne (ASX:TNE) Long-Term ASX Shares to Watch?

Highlights ResMed continues expanding its connected healthcare and sleep therapy business across global markets. TechnologyOne is strengthening its cloud software platform through long-term customer relationships and recurring revenue. Healthcare innovation and enterprise software remain important structural growth themes across the Australian market. ResMed Inc (ASX:RMD) and TechnologyOne Ltd (ASX:TNE) continue attracting attention as two established Australian compa...

Continue reading
Kalkine
Neutral
just now

What Makes ResMed (ASX:RMD) A Health Quality Check?

Highlights ResMed is being watched through sleep health demand as the ASX mood stays selective. Healthcare Stocks screens are shifting toward device demand and channel strength instead of broad market excitement. CSL and Pro Medicus add context for readers comparing medical devices exposure. The Australian share market has entered the new session with a familiar but sharper test: where is reliable evidence hiding when index direction is uneven? ResMed (ASX:RMD), sleep ...

Continue reading
Kalkine
Neutral
just now

ResMed (ASX:RMD) Trades Below Global MedTech Peers As Value Focus Returns

Highlights ResMed (ASX:RMD) has retreated despite continued operational momentum across its sleep and respiratory care business. The healthcare company is trading below valuation levels typically seen among global medical technology peers. Temple & Webster (ASX:TPW) also features among Australian companies attracting attention as a value-oriented growth story. ResMed Limited (ASX:RMD), the Australian-founded global medical technology company specialising in sleep ...

Continue reading
Kalkine
Positive
just now

What Does ResMed's (ASX:RMD) MatrixCare Sale Mean for Its Future Growth Strategy?

Highlights ResMed has agreed to divest its MatrixCare business as part of its ongoing portfolio optimisation strategy. The company plans to use the proceeds to support share repurchases and broader corporate initiatives. The transaction strengthens ResMed's focus on its core sleep health, respiratory care and connected care businesses. ResMed Inc. (ASX:RMD) has announced the divestment of its MatrixCare business, marking another strategic step in refining its healthca...

Continue reading
Kalkine
Neutral
just now

Why Are ResMed (ASX:RMD) Shares in Focus as ASX Preview Signals a Mixed Monday?

Highlights Australian shares are set for a softer opening despite positive momentum across major European markets. Rising gold and firmer crude oil prices are placing resource and energy companies under renewed attention. Healthcare, shipbuilding and commodity-linked companies headline the market watchlist for the new trading week. Australian shares begin the week with mixed global signals as en...

Continue reading
Kalkine
Positive
just now

Can ResMed (ASX:RMD) and Pro Medicus Lead the Next Growth Revival?

Highlights Healthcare is emerging as a key focus as quality businesses regain attention across the Australian share market. ResMed (ASX:RMD), Pro Medicus (ASX:PME), CSL (ASX:CSL) and Cochlear (ASX:COH) highlight how the market is rewarding stronger business fundamentals over broad sector enthusiasm. A more selective market backdrop is encouraging closer attention to cash generation, operational consistency and balance sheet strength. ...

Continue reading
Kalkine
Neutral
just now

ResMed (ASX:RMD): Why Is Healthcare Software Standing Out?

Highlights Healthcare stocks are drawing fresh ASX attention as software-linked exposure adds a stronger quality lens. ResMed, Sonic Healthcare and Pro Medicus show different parts of the healthcare sector. Market focus is shifting toward execution, recurring demand and clearer business resilience. Healthcare stocks are gaining fresh ASX attention as ResMed, Sonic Healthcare, Pro Medicus, CS...

Continue reading
Kalkine
Positive
just now

ResMed (ASX:RMD) Pushes Back Against GLP-One Market Fears

Highlights ResMed’s latest quarterly update challenges concerns that weight-loss medicines could weaken demand for sleep apnoea devices. Strong revenue momentum and improved margins have helped reshape the conversation around the healthcare company. The broader [ASX 200] healthcare landscape is watching whether sleep therapy demand remains resilient. ResMed has found itself at the centre of one of the biggest healthcare debates on ...

Continue reading
Kalkine
Neutral
just now

ResMed (ASX:RMD): Why Are Healthcare Stocks Under Watch?

Highlights ASX healthcare stocks are being judged through earnings proof, not headline momentum. Margin repair, clinical demand and reimbursement settings are shaping the sector debate. ResMed, Sonic Healthcare and Ramsay Health Care are framing the new financial year healthcare story. ASX healthcare stocks face a sharper new financial year test as margin repair, clinical demand and reimburs...

Continue reading
Kalkine
Neutral
just now

Why Is ResMed (ASX:RMD) Winning Back the ASX 200 Healthcare Story?

Highlights ResMed has delivered solid quarterly growth as concerns surrounding GLP-one therapies ease. Revenue growth and stronger operating margins have reinforced confidence in the company's core business. Continued demand for sleep-related healthcare solutions has strengthened Australia's Healthcare Stocks sector. ResMed's latest quarterly performance hig...

Continue reading
Kalkine
Neutral
just now

Why ResMed (ASX:RMD) Is Rebuilding Confidence on the ASX 200?

Highlights ResMed remained operationally resilient despite broad healthcare sector weakness. Competitive concerns surrounding weight-loss therapies have eased as demand stays stable. The global medical technology leader continues attracting attention across Healthcare Stocks . ResMed continues demonstrating resilient healthcare demand through respiratory dev...

Continue reading
Kalkine
Neutral
just now

Is RMD (ASX:RMD) Leading a Healthcare Turnaround Signal?

Highlights ResMed (ASX:RMD) is under close watch as ASX healthcare sentiment remains weak across the sector. The stock has fallen significantly over the past year while some analysts flag it below fair value estimates. ASX healthcare remains under pressure as investors debate whether the selloff has overshot fundamentals. ResMed (ASX:RMD) is in focus as ASX healthcare remains under pressure, with investors debating whether the sector’s selloff has gone beyond fundamentals. Austral...

Continue reading
Kalkine
Neutral
just now

ResMed (ASX:RMD) Leads Healthcare Stocks as EOFY Flows Shift Focus

Highlights Device diagnostics momentum is drawing fresh attention to healthcare names as EOFY positioning reshapes market activity. ResMed, Cochlear and Pro Medicus are emerging as key reference points in the latest healthcare sector conversation. Market participants are focusing more closely on cash flow visibility, execution strength and valuation discipline amid a cautious backdrop. The Australian share market is entering a critical EOFY period with heightened attention on sector-specific ...

Continue reading
Kalkine
Neutral
just now

Are (ASX:RMD) and Healthcare Shares Near a Turning Point?

Highlights ASX healthcare shares remain under pressure after a prolonged 2026 downturn across the sector. ResMed Inc (ASX:RMD) has attracted attention as valuations reset across global healthcare names. Investors are reassessing whether defensive healthcare positioning is nearing a sentiment shift. ASX healthcare stocks remain under pressure, with ResMed (ASX:RMD) at the centre of valuation discussions as investors reassess sector positioning and long-term growth outlook. Australian equ...

Continue reading
Kalkine
Neutral
just now

Watch ResMed’s GLP-1 Fear Fade as Data Tells a Different Story

Highlights ResMed (ASX:RMD) has been pressured by concerns that GLP-1 drugs could reduce sleep apnoea device demand. Real-world evidence suggests patients often use GLP-1 therapies alongside CPAP treatment. Sentiment across ASX healthcare is shifting as fears are reassessed against actual clinical behaviour. ResMed has been pressured by GLP-1 fears, but real-world data shows combined therapy use is common. This challenges disruption concerns and reshapes sentiment across ASX healthcare ...

Continue reading
Kalkine
Neutral
just now

RMD Shares on Watch as Healthcare Trends Shift in 2026

Highlights ResMed continues to attract attention as global healthcare demand and sleep disorder treatments remain structurally relevant. Valuation discussions highlight the tension between long-term growth expectations and recent market re-rating. Sector rotation in the [ASX 200] is shaping sentiment across major healthcare names including ResMed. ResMed continues to attract market attention as healthcare trends evolve, with global demand, digital health growth and valuation debates sha...

Continue reading
Kalkine
Neutral
just now

Why Are ResMed Shares Under Pressure Despite Solid Results?

Highlights ResMed shares declined despite broader market strength as concerns around weight-loss drugs resurfaced. Market attention remains focused on the long-term impact of obesity treatments on sleep apnea therapies. The company continues to report strong operational performance while expanding into adjacent healthcare segments. ResMed shares remain under pressure as investors assess whether obesity treatments could reshape sleep apnea markets, despite the company continuing to deliver str...

Continue reading
Kalkine
Neutral
just now

Why Is (ASX:RMD) Drawing Attention in 2026?

Highlights Strong global footprint across healthcare solutions Balanced mix of hardware and software offerings Financial position reflects stability and flexibility ResMed continues to attract attention due to its expanding healthcare ecosystem, steady revenue trajectory, and resilient financial structure, making it a closely watched name within the broader Australian market landscape. Understanding the Momentum Behind (RMD) The keyword Are Resmed CDI (ASX:RMD) shares good value in 2026...

Continue reading
Kalkine
Neutral
just now

ResMed Share Price Insights: Is RMD Worth Watching in 2026?

Highlights Strong revenue expansion supports long-term growth narrative Balanced financial structure with solid cash position Valuation levels appear below historical trend ResMed CDI (RMD) continues to demonstrate steady business momentum, supported by global demand in healthcare technology. A closer look at financial metrics reveals how growth, margins, and valuation trends shape its current market position. Understanding ResMed CDI (RMD) Share Value in 2026 The keyword Resmed CDI (AS...

Continue reading